Stockscreener 앱 받기
0.2272
4.82%
-0.0115
시장 영업 전:
.22
-0.0072
-3.17%
Hcw Biologics Inc 주식(HCWB)의 최신 뉴스
HCW Biologics Stock Set to Reverse Split on Friday, April 11th (NASDAQ:HCWB) - Defense World
HCW Biologics to Implement 1-for-40 Reverse Stock Split - MarketScreener
HCW Biologics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com South Africa
HCW Biologics Announces 1-for-40 Reverse Stock Split - citybiz
HCW Biologics approves reverse stock split - Investing.com India
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCW Biologics approves reverse stock split to meet Nasdaq rules - Investing.com
HCW Biologics approves 1-for-40 reverse stock split - TipRanks
HCW Biologics Announces 1-For-40 Reverse Stock Split - MarketScreener
Major Stock Restructuring: HCW Biologics Announces 40:1 Reverse Split for Nasdaq Compliance - Stock Titan
Warner Bros Discovery Stock (NASDAQ:WBD) Slides as Film Boss Replacements Considered - The Globe and Mail
HCW BIOLOGICS Earnings Preview: Recent $HCWB Insider Trading, Hedge Fund Activity, and More - Nasdaq
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - GlobeNewswire
HCW Biologics Inc. SEC 10-K Report - TradingView
HCW Biologics Secures FDA Green Light for Alopecia Treatment Despite $30M Annual Loss - Stock Titan
HCW Biologics amends agreement with WY Biotech amid delays - Investing.com
Stocks Attempt to Stabilize as Trump Set to Meet with Top US Executives - The Globe and Mail
HCW Biologics Granted Extension by the Nasdaq Hearings - GlobeNewswire
HCW Biologics Inc. Receives Extension from Nasdaq to Regain Compliance with Listing Rules - Nasdaq
Can HCW Biologics Meet Nasdaq's New June Deadline? Key Details Revealed - StockTitan
HCW Biologics Inc. announced that it expects to receive $20 million in funding -February 19, 2025 - Marketscreener.com
Zeta (ZETA) Q4 Earnings: What To Expect - The Globe and Mail
HCW Biologics Inc (HCWB) is looking forward to a strong quarter - SETE News
HCW Biologics Inc Inc. (HCWB) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Navigating the Volatility of HCW Biologics Inc’s (HCWB) Stock - The News Heater
Trading Day Review: HCW Biologics Inc (HCWB) Loses Momentum, Closing at 0.43 - The Dwinnex
The Business Case For Buying HCW Biologics Inc (NASDAQ: HCWB) Stock Now - Stocks Register
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
HCW Biologics: Buy Rating Affirmed Amid IND Clearance and Strategic Advancements - TipRanks
HCW-9302 gains IND clearance for first-in-human study in alopecia areata - BioWorld Online
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
HCW Biologics Inc Inc. (HCWB) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Penny Stocks To ResearchFebruary 03rd - MarketBeat
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Pharma company granted FDA clearance for alopecia drug study - The Business Journals
Crude Oil Moves Higher; Owens & Minor Shares Plummet - Benzinga
FDA approves HCW Biologics trial for alopecia treatment - MSN
What's Going On With HCW Biologics Stock Monday? - Benzinga
A Potential Breakthrough in the Fight Against Alopecia Areata: What You Need to Know About HCW Biologics Inc. - RagingBull
Stock market news: MDJM surged by 74.54% while Tonix Pharmaceuticals Holding plunged by 49.31% during mid day trading - Business Upturn
Dow Falls 150 Points; ISM Manufacturing PMI Rises In January - Benzinga
S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results - Benzinga
HCW Biologics Advances with FDA Clearance for Trial - TipRanks
Stock market today: Tonix Pharmaceuticals Holding declined by 49.01% whereas HCW Biologics jumped by 176.78% in early trading - Business Upturn
HCW Biologics Says FDA Approves Trial of HCW9302 to Treat Alopecia Areata; Shares Rise Pre-Bell - Marketscreener.com
HCW Biologics Granted FDA Clearance to Evaluate One of the - GlobeNewswire
HCW Biologics Granted FDA Clearance to Evaluate One of the Company?s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial - Marketscreener.com
HCWB stock touches 52-week low at $0.25 amid market challenges - Investing.com Australia
HCW Biologics (NASDAQ:HCWB) Shares Down 20% – Here’s Why - Defense World
HCWB stock touches 52-week low at $0.25 amid market challenges By Investing.com - Investing.com South Africa
HCW Biologics Insiders Placed Bullish Bets Worth US$2.50m - Yahoo Finance
HCW Biologics (HCWB) Stock Price, News & Analysis - MarketBeat
HCW Biologics : January 2025. - Marketscreener.com
HCW Biologics’ Founder and CEO to Address Opportunities and - GlobeNewswire
HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 - The Manila Times
HCW Biologics CEO to Share Breakthrough Immunotherapy Insights at 2025 GenScript Forum - StockTitan
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 - Yahoo Finance
3.01%
자본화:
|
볼륨(24시간):